Roche and GLYCART to discover new therapeutic antibodies
"We have rapidly generated GlycoMAbTM versions of Roche's antibody with dramatically enhanced potency, and we are pleased that after this initial technology evaluation, Roche has decided to license GlycoMAbTM," said Pablo Uma?a, PhD, CSO of GLYCART. Joël Jean-Mairet, PhD, CEO of GLYCART, added, "The significance of bringing our technology to a global antibody player such as Roche cannot be underestimated. Clearly, this collaboration will be invaluable to GLYCART in continuing to forge partnerships with the leading antibody companies."
"In the first quarter of this year, 49 percent of Roche's sales came from biotechnology products," explained Peter Hug, Roche's Global Head of Pharma Partnering. "To maintain and expand our leadership in the antibody market, and in disease areas such as oncology, Roche will continue to partner with excellent antibody companies such as GLYCART."
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous